13 companies received permission to test hepatitis C drugs – Kommersant
[ad_1]
13 companies in Russia received permission to conduct clinical trials of drugs for the treatment of hepatitis C. This was announced by the head of the Ministry of Health of Russia Mikhail Murashko.
“Today, 13 companies have received permission to conduct clinical trials. Two companies are now undergoing an examination, and we are waiting for the decision of the board of the ethical committee to issue a permit for clinical trials,” Mr. Murashko said at the meeting Council for Strategic Development and National Projects with Russian President Vladimir Putin.
Mikhail Murashko also said that Russian companies are ready to give discounts of 20-30% on drugs for the treatment of hepatitis C as part of the centralization and growth in purchases. According to him, the funding system was also divided for each case, which allowed to increase the number of patients who received treatment for hepatitis C by 35%.
The day before, Kommersant wrote that the American pharmaceutical manufacturer MSD had warned the Ministry of Health of the Russian Federation and Roszdravnadzor about stopping the supply of Zepatier to Russia. According to Kommersant, the company has already notified its Russian partners about changes in trade policy, but we are not talking about an instant halt in exports. The decision will not affect deliveries scheduled for 2024.
“Zepatier” is one of the three most popular regimens for the treatment of hepatitis C 1, 3 and 4 genotypes in adults. Last year, its share in state-paid purchases of relevant drugs amounted to 19%, in the first half of 2023 – 18%.
More details – in the material “Kommersant” “Pharmaceutical market falls into hepatia”.
[ad_2]
Source link
